An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

Thomas H Wang, Deepak L Bhatt, Keith A A Fox, Steven R Steinhubl, Danielle M Brennan, Werner Hacke, Koon-Hou Mak, Thomas A Pearson, William E Boden, P Gabriel Steg, Marcus D Flather, Gilles Montalescot, Eric J Topol, CHARISMA Investigators

Research output: Contribution to journalArticlepeer-review

71 Citations (Scopus)


To examine the unanticipated, excess mortality observed in patients randomized to clopidogrel and aspirin vs. aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population.
Original languageEnglish
Pages (from-to)2200-7
Number of pages8
JournalEuropean Heart Journal
Issue number18
Publication statusPublished - Sep 2007


  • Aged
  • Aspirin
  • Atherosclerosis
  • Cardiovascular Diseases
  • Disease-Free Survival
  • Drug Therapy, Combination
  • Epidemiologic Methods
  • Female
  • Hemorrhage
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Platelet Aggregation Inhibitors
  • Stroke
  • Ticlopidine

Cite this